PAHCNasdaqPharmaceutical PreparationsFiscal year ends June 30
PHIBRO ANIMAL HEALTH CORP
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 26, 2026
$39.34+0.52 (+1.34%)
Close on Oct 19, 2026
- Market cap
- $1.61B
- P/E (TTM)
- 16.2
- Dividend yield
- 1.22%
Share price
−$0.38 (−0.96%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsEx-dividend
PHIBRO ANIMAL HEALTH CORP grew revenue 17.1% to $1.52B over the twelve months to Jun 30, 2026. Operating income rose 76.0% to $194.40M, moving the operating margin from 8.5% to 12.8%. Free cash flow was $9.87M, down 76.4% from a year earlier.
Revenue
$1.52B
+17.1% vs. a year earlier
Operating income
$194.40M
+76.0% vs. a year earlier
Free cash flow
$9.87M
-76.4% vs. a year earlier
EPS, diluted
$2.43
+104.2% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.61B
- P/E ratio
- 16.2
- Price to sales
- 1.06
- Price to book
- 4.18
- Dividend yield
- 1.22%
- Free cash flow yield
- 0.61%
Fundamentals
- Revenue
- $1.52B
- Net income
- $99.72M
- EPS, diluted
- $2.43
- Free cash flow
- $9.87M
- Book value per share
- $9.40
- Diluted shares
- 41M
Fifteen years at a glance
Fiscal years 2012 to 2026, USD
Revenue
$1.52B+17.1% YoY
Gross profit
$512.52M+28.1% YoY
Operating income
$194.40M+76.0% YoY
Net income
$99.72M+106.6% YoY
EPS, diluted
$2.43+104.2% YoY
Free cash flow
$9.87M-76.4% YoY
Reported period